Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.


Shareholder Alert: Robbins LLP Announces Elanco Animal Health Incorporated (ELAN) Accused of Misleading Shareholders


Shareholder rights law firm Robbins LLP announces that a purchaser of Elanco Animal Health Incorporated (NYSE: ELAN) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between January 10, 2020 and May 6, 2020. Elanco is an animal health company that develops, manufactures, and markets products for companion and food animals.

If you suffered a loss as a result of Elanco’s misconduct, click here.

Elanco Animal Health Incorporated (ELAN) Accused of Misleading Shareholders

According to the complaint, on March 24, 2020, Elanco withdrew its previously announced 2020 revenue and earnings per share guidance in light of the coronavirus pandemic. However, Elanco assured investors “the Company is closely monitoring distribution logistics” and that “at this time, Elanco is not experiencing any supply disruption.” Despite these assurances, on May 7, 2020, Elanco announced its first quarter 2020 results revealing revenue of $657.7 million and earnings per share of negative $0.12, reflecting a reduction of approximately $60 million in channel inventory. Elanco attributed the disappointing financial results to “distributor performance,” among other things and assured investors the Company would “tighten [its] approach across many facets of [its] distributor relationships.” On this news, Elanco’s share price fell over 13% to close at $19.88 per share.

Elanco Animal Health Incorporated (ELAN) Shareholders Have Options

Contact us to learn more: Leo Kandinov (800) 350-6003 Shareholder Information Form

Want to be notified if a class action on behalf of Elanco settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Leo Kandinov

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122

(619) 525-3990 or Toll Free (800) 350-6003

Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now


Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.